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Background: Down syndrome (DS) is a complex disorder caused by the trisomy of either the entire, or a critical
region of chromosome 21 (21q22.1-22.3). Despite representing the most common cause of mental retardation, the
molecular bases of the syndrome are still largely unknown.
Methods: To better understand the pathogenesis of DS, we analyzed the genome-wide transcription profiles of
lymphoblastoid cell lines (LCLs) from six DS and six euploid individuals and investigated differential gene expression
and pathway deregulation associated with trisomy 21. Connectivity map and PASS-assisted exploration were used
to identify compounds whose molecular signatures counteracted those of DS lymphoblasts and to predict their
therapeutic potential. An experimental validation in DS LCLs and fetal fibroblasts was performed for the most
deregulated GO categories, i.e. the ubiquitin mediated proteolysis and the NF-kB cascade.
Results: We show, for the first time, that the level of protein ubiquitination is reduced in human DS cell lines and that
proteasome activity is increased in both basal conditions and oxidative microenvironment. We also provide the first
evidence that NF-kB transcription levels, a paradigm of gene expression control by ubiquitin-mediated degradation, is
impaired in DS due to reduced IkB-alfa ubiquitination, increased NF-kB inhibitor (IkB-alfa) and reduced p65 nuclear
fraction. Finally, the DSCR1/DYRK1A/NFAT genes were analysed. In human DS LCLs, we confirmed the presence of
increased protein levels of DSCR1 and DYRK1A, and showed that the levels of the transcription factor NFATc2 were
decreased in DS along with a reduction of its nuclear translocation upon induction of calcium fluxes.
Conclusions: The present work offers new perspectives to better understand the pathogenesis of DS and suggests a
rationale for innovative approaches to treat some pathological conditions associated to DS.
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Down syndrome (DS) (MIM 190685) is a human complex
disorder caused by the trisomy of either the entire, or a
critical region of chromosome (chr) 21 (21q22.1-22.3). DS
phenotypes are often variable. Intellectual disability and
hypotonia are the hallmarks of the syndrome, while a* Correspondence: andria@unina.it
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reproduction in any medium, provided the orwealth of distinct clinical manifestations, including con-
genital malformations, increased incidence of cancer, im-
mune and endocrine abnormalities occur only in subsets
of DS subjects. DS is also characterized by premature
aging and dementia with neurological features that mimic
those found in Alzheimer’s disease. The underlying mo-
lecular mechanisms of DS are largely unknown. Several
genome-wide expression studies have been performed
both in mouse and human trisomic tissues. While DS
mice models have unravelled a generalized overexpression
of triplicated genes [1-4], the analysis of human DS tissuesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reported the selective over-expression of a limited subset
of chr 21 genes [5-9], and others described subtle
upregulations of chr 21 genes associated to a secondary,
generalized and more extreme transcriptional deregula-
tion of genes mapping on other chromosomes [10-15]. An
additional level of complexity comes from the observation
that gene expression differs extensively among unaffected
individuals [16-19], including the expression of a number
of chr 21 genes [20,21]. Therefore, some authors sug-
gested to regard as poor candidates for DS pathogenesis
those genes with high expression variation among controls
and as reliable candidates those genes over-expressed in
DS and tightly regulated in euploid cells [21-23]. Gene ex-
pression studies failed to provide definitive results; how-
ever, evidence in human DS cells point to the presence of
abnormalities of extracellular matrix, of mitochondrial
function and other metabolic pathways, including purine
metabolism, in fetal specimens [5,11,13], and changes in
transcriptional regulation, oxidative stress and immune-
related genes in adult tissues [6,12,14,24,25]. Recently, the
effect of single chr 21 genes on the trisomic trancriptome
was established by comparing the genome-wide expres-
sion from mouse ES cells, engineered to host the whole
human chr 21, with those overexpressing only single chr
21 genes. A subset of genes, including Runx1, Erg, Nrip,
Olig2, PdxK and Aire, produced the strongest tran-
scriptional response when overexpressed [26]. More
recently, Vilardell et al. [27] performed a meta-analysis
from 45 publicly available DS data sets, from both hu-
man and mouse transcriptome and proteome. The
identified biological functions were mainly related to
nervous system development, neurodegenerative disor-
ders (e.g. Huntington’s disease, Alzheimer’s disease and
Parkinson’s disease) and defects in synapsis function
(e.g. axon guidance, NGF signalling). Seventy distinct
transcription factors, including RelA, NFATc1, NFATc2
and NFATc3, were identified as being affected by dos-
age imbalance.
Besides genome-wide expression analysis, few studies
attempted to identify selected gene networks associated
to specific DS features and to characterize molecular
and biochemical functions disrupted in DS. In mice,
Arron et al. [28] found that two critical chr 21 genes
(DYRK1A and DSCR1, also known as RCAN1) act syn-
ergistically to control the nuclear localization of NFAT
family of transcription factors and that knock-out mice
for NFATc1, NFATc2, NFATc3 and NFATc4 display car-
diovascular, neurological, skeletal and immune pheno-
types strikingly similar to DS. In addition, DSCR1
promotes neurotoxicity [29] and attenuates the inflam-
matory response by stabilizing IkB-alfa [30]. The extra
copy of DYRK1A in DS has been also associated to early
onset of Alzheimer’s disease [31] and to defectiveneuronal development mediated by the reduction of
REST, a key regulator of pluripotency and neuronal dif-
ferentiation [32]. DSCR1/NFAT pathway was also associ-
ated with neuronal susceptibility to oxidative stress [33],
a biochemical feature of DS. Finally, a limited number of
functional studies in human DS cells have unravelled a
disruption of mitochondrial function as a pathogenetic
trigger [34-37].
In this study we analyzed the genome-wide transcrip-
tion profile of lymphoblastoid cell lines (LCLs) from DS
and control subjects to investigate differential gene ex-
pression and pathway deregulation associated with tri-
somy 21. This cellular model has been widely used to
analyze the expression profiles of chr 21 genes [21,23,38]
as well as of other diseases including cancer [39-41] and
neurodegenerative disorders [42,43]. Diseased versus
control and intra-group comparisons were used to
analyze the gene expression levels of chr 21 genes. The
experimental validation focused on the most deregulated
gene ontology (GO) categories to confirm their imbal-
ance in DS, i.e. the ubiquitin mediated proteolysis and
the NF-kB cascade. Interestingly, these two celullar pro-
cesses are closely interconnected since IkB-alfa, the key
modulator of NF-kB, can be regarded as a model protein
of regulation of signal transduction by the ubiquitin-
proteasome system (UPS). Moreover, both the ubiquitin
mediated proteolysis and the IkB/NF-kB signal trans-
duction interact with and regulate DSCR1 [44]. In
mice, DSCR1 and DYRK1A act synergistically to pre-
vent the nuclear occupancy of NFAT [28], a family of
transcription factors activated by calcium fluxes. Fi-
nally, DSCR1 is ubiquitinated and degraded by both
the proteasome and the autophagy-lysosome pathways
[45]. As these pathways are interconnected and indi-
vidually can cause immune response derangement,
neurodegenerative diseases, premature aging and delay
of cell growth, all main features of DS, our experimen-
tal validation focused on UPS, NF-kB and DYRK1A/
DSCR1/NFAT genes. In human LCLs and fetal fibro-
blasts, we provide the first evidence that the level of
protein ubiquitination is reduced in DS and that prote-
asome activity is increased in both basal conditions
and oxidative microenvironment. In addition, we first
show that the NF-kB transcriptional activity is im-
paired in DS due to reduced IkB-alfa ubiquitination,
increased NF-kB inhibitor (IkB-alfa) cytosolic levels
and reduced p65 nuclear fraction. Finally, the investi-
gation of DSCR1/DYRK1A/NFAT genes, linked to the
pathogenesis of DS in animal studies, confirmed in-
creased protein levels of DSCR1 and DYRK1A and
showed reduced levels of NFATc2 and decreased
NFATc2 nuclear translocation upon calcium flows in-
duction, adding new evidence to a transcriptional
regulation deficit in DS.
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Cell culture
LCLs were generated from peripheral blood samples of six
karyotypically confirmed full trisomy 21 children and six
age-matched controls (5 ± 1 year-old) recruited at the De-
partment of Pediatrics, Federico II University of Naples.
The study was performed in accordance with the princi-
ples of the Helsinki Declaration and was approved by the
Federico II University Ethics Committee ‘Carlo Romano’.
The parents of all subjects gave written informed consent
before participation. Lymphocytes were isolated by ficoll-
hypaque (Gibco) and resuspended in 17% FBS-RPMI-
1640 and equal volume of supernatant from overgrown
B95.8 cell cultures in presence of 10 μg/ml of cyclosporine
(Sandimmune Oral Suspension). Cells were grown in
17% FBS-RPMI-1640 (Cambrex) supplemented with
5000 U/ml penicillin-streptomycin, 2 mM glutamine
(Gibco) and 0.16 mg/ml gentamicin, in a 37°C, 5% CO2
incubator.
Fibroblasts from two DS and two control fetuses,
spontaneously aborted at a gestational age between 14
and 19 weeks, were obtained from the Galliera Genetic
Bank (Galliera Hospitals, Genova, Italy) in agreement
with ethical guidelines stated in the TGB Network Char-
ter and upon written informed consent. Cells were cul-
tured at 37°C in D-MEM medium (Gibco) supplemented
with 17% FBS, 5000U/ml penicillin-streptomycin, 2 mM
glutamine (Gibco), in a 37°C, 5% CO2 incubator. For
functional analyses, sub-confluent cultures with compar-
able number of culture passages (5–15) and growth rate
were used. Each aliquot of LCLs was maintained in cul-
ture for no longer than 3 months (less than 160 ‘popula-
tion doubling levels’) [46]. To exclude the possibility of
chromosomal rearrangements (other than full trisomy
21) during culturing, LCLs were karyotyped before
microarray analysis and before each experimental
validation.
Cell treatment
Calcium flows were induced with 10 ng/ml PMA and
1 mg/ml Ionomycin (Sigma) for 4 hours at 37°C. For the
proteasome blocking, cells were treated with 40 μM
MG132 (Calbiochem) for 6 hours at 37°C for western blot
experiments and 100 μM MG-132 for 2 hours for prote-
asome assay. Oxidative stress was induced with 0.1 mM
H2O2 for 30 minutes and recoveries were observed 1, 2
and 4 hours after cell refreshing with RPMI without
H2O2. Phospho-IkB-alfa was analyzed after cell treatment
with 40 μM MG132 for 30 minutes and incubation with
0.3 μM Calyculin A for an additional 30 minutes [47].
RNA extraction and microarray hybridization procedure
RNAs from six DS and six control LCLs were independ-
ently hybridized on the Affymetrix HU133 plus 2.0oligonucleotide array (Affymetrix, Santa Clara, CA),
which allows the analysis of over 47,000 human tran-
scripts including 38,500 well-characterized human genes.
Total RNAs were obtained using TRIzol reagent (Gibco/
BRL Life Technologies, Inc., Gaithersburg, MD) and
used to prepare biotinylated target cRNA, according
to the Affymetrix procedures. Quality and amount
of starting RNA were confirmed using spectrophotom-
etry and agarose gel electrophoresis. Purification of
PolyA +mRNA from total RNA was performed with the
Oligotex mRNA Kit (QIAGEN GmbH, Hilden, Germany):
1 μg of mRNA was used to generate first-strand cDNA by
using a T7-linked oligo(dT) primer; after second strand
synthesis, in-vitro transcription was performed with
biotinylated UTP and CTP using the Enzo BioArray High
Yield RNA Transcript Labeling Kit (Enzo Diagnostics,
Farmingdale, NY). The target cRNA generated from each
sample was processed according to the manufacturer’s
procedures. Fragmentation of biotinylated cRNA, washing
and staining were done according to the instructions pro-
vided by Affymetrix.
Experimental design
The experimental design was a diseased versus control
comparison. To assess the expression variation of chr 21
genes among DS and control samples, we focused our
analysis on the variability of all chr 21 transcripts
present on the array with FC ≥ 1.2 (n = 167), irrespective
of the statistical analysis that excludes ‘a priori’ variable
genes. Gene variability was assessed by the CV, calcu-
lated as the ratio between standard deviation and mean
expression levels for each gene among samples [22].
Arbitrary cut-offs were set at 0.2 and 0.5 and tran-
scripts were divided into three classes: CV ≤ 0.2, corre-
sponding to the tightly regulated genes; 0.2 < CV < 0.5,
corresponding to genes with little variation; CV ≥ 0.5,
corresponding to highly variable genes.
Data acquisition and processing
After scanning, array images were assessed by eye to
confirm scanner alignment and the absence of signifi-
cant bubbles or scratches on the chip surface. 3’/5’ ratios
for GAPDH and beta-actin were confirmed to be within
acceptable limits (0.70–1.64), and BioB spike controls
were found to be present on all chips, with BioC, BioD
and CreX also present in increasing intensity. Array
scanning data (CEL files) were processed using the RMA
algorithm [48]. GeneSpring software (Silicon Genetics,
Redwood City, CA) was used for data mining. Raw ex-
pression data were normalized per gene by dividing each
measurement for each gene by the median of that gene’s
measurements in the corresponding control non-trisomic
samples. Normalized data were log-transformed. To re-
duce the noise and the variability induced by several
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experimental procedures [49], expression data were
pre-filtered and genes were considered suitable for dif-
ferential evaluation if called present in at least 4 out of
6 samples. Microarray data were submitted to ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) database (accession n.
E-MTAB-1238). Statistical evaluation was performed by
Welch t-test, corrected with Benjamini-Hochberg FDR al-
gorithm and filtered for fold-changes in DS vs controls ≥
1.2. Statistical significance was assessed at 0.05 and, for a
further analysis, at 0.01. Supervised classification of samples
was performed using hierarchical clustering (GeneSpring
software).
Bioinformatics data analyses
GO and pathway analyses of gene lists were performed
using David Bioinformatics software (http://david.abcc.
ncifcrf.gov/) [50]. For GO functional class scoring, a
modified Fisher exact test (EASE score) was used and
the statistical significance was set at p-value < 0.05. The
fold enrichment (FE) value was used as a measure of the
magnitude of enrichment. To compare results and to
highlight more reliable GO classes, a second web-based
software was used, the Gene Ontology Tree Machine
(GOTM) [51]. To identify compounds with molecular
signatures that might mitigate the effects of trisomy 21,
Connectivity Map build 0.2 was used. The database con-
tains 564 expression profiles representing the effects of
164 compounds on 4 cancer cell lines, using the
Affymetrix U133 microarrays [52]. Because the U133
plus 2.0 array contains a greater number of probe-sets,
the Connectivity Map analysis was performed using only
the probe-sets common to both arrays. A list of
perturbagens, hypothetically connected (positively and
negatively) with the signature of interest was generated
according to the permutation p. Perturbagenes with
negative enrichment scores (< −0.7) were considered
connected to the reversal or repression of the biological
state encoded in the query signature. Perturbagens with
enrichment scores < −0.7 and p-value < 0.05 were en-
tered in the PASSonline software (Prediction of Activity
Spectra for Substances) [53,54] in order to estimate their
predicted activity. The current version of PASS available
online (http://www.pharmaexpert.ru/passonline/index.php)
predicts around 3750 pharmacological effects, biochemical
mechanisms of action, specific toxicities and metabolic
terms on the basis of structural formulae of drug-like sub-
stances with average accuracy ~ 95%. The predicted activity
spectrum of a compound is estimated as probable activity
(Pa) and probable inactivity (Pi) and only activities
with Pa > Pi are considered. When Pa > 0.7, there is a
high chance to confirm the activity experimentally,
while if 0.5 < Pa < 0.7, the probability is lower but there
is more than 50% chance for the compound to be anovel therapeutic molecule. Only compounds with Pa > 0.5
were considered here as potential therapeutic molecules.
Quantitative Real-Time PCR
Single stranded cDNA was synthesized with random
hexamer primers starting from 2 μg of total RNA using the
High Capacity cDNA Archive Kit (Applied Biosystems).
Real-time PCR was performed using 2 μl of cDNA and
TaqMan Universal PCR MasterMix 2X on the Applied
Biosystems 7300, according to the manufacturer’s pro-
cedures. PCR reactions were performed in triplicate.
Beta-2-microglobulin and ring finger protein 111
(RNF111) housekeeping genes were chosen as refer-
ence genes [55,56].
Protein extraction
Total protein extraction was carried out by cell incubation
with the Tropix lysis solution (Applied Biosystems)
supplemented with 0.1 M DTT in the presence of prote-
ase inhibitor cocktail 1X (Sigma). To better visualize
protein-linked ubiquitins, lysis solution was supplemented
with 5 mM manganese and 50 μM MG132 according to
Mimnaugh and Neckers [57]. Cytoplasmic and nuclear
fractions were obtained by celLytic NucLEAR Extraction
kit (Sigma).
Immunoprecipitation
Immunoprecipitation was carried out incubating 500 μg –
1 mg cytoplasmic extracts with specific antibodies at 4°C
for 2 hours. Dynabeads Protein G (Invitrogen) were added
to the mixture and the incubation was continued for other
2 hours. Proteins complexed with antibody - Dynabeads
Protein G were immunoprecipitated and washed for three
times with the use of a magnet, and finally eluted by boil-
ing in SDS sample buffer for 10 minutes.
Western blot analysis
Protein extracts (25–45 μg) were separated by 7-10%
SDS-PAGE and then transferred on PVDF membrane
(Millipore). Membranes were then blocked for 1 hour in
5% milk-1X PBS-0.1% Tween-20 (T-PBS) and then incu-
bated from 4 hours to overnight with dilutions of spe-
cific primary antibodies: 1:1000 anti-NFATc1 (H-110),
1:100 anti-NFATc2 (4G6-G5), 1:1000 anti-NFATc3 (M-75),
1:1000 anti-NFATc4 (H-74), 1:2500 anti-DYRK1A (H-143)
(SantaCruz); 1:1000 anti-DSCR1 (N-20) (SIGMA); 1:2000
anti-NF-kB p65 (Upstate); 1:1000 anti-NF-kB p50 (Up-
state); 1:1500 anti-IkB-alfa (L35A5), 1:1000 anti-pIkB-alfa
(Ser32/36), 1:1000 anti-ubiquitin (P4D1) (CellSignaling).
1:2000 anti-α-Tubulin (SIGMA) and 1:1000 Histone H1
(SPM 256) (SantaCruz) were used to normalize the levels
of total, cytosolic and nuclear proteins. As secondary
antibodies, 1:5000 anti-mouse, 1:2000 anti-rabbit and
1:2000 anti-goat IgG horseradish peroxidase conjugated
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sualized by ECL plus reaction (GE-Healthcare).
Luciferase assay
To test NF-kB transcriptional activity, LCLs from DS sub-
jects and controls were plated in 24-well plates at density
of 5x105 cells/well and transfected, 24 hours later, with
pNF-kB-Luc (Path Detect NF-kB Cis-Reporting System,
Stratagene) and pSV-β-Gal plasmid by using Turbofect
Transfection Reagent (Fermentas), according to the
manufacturer’s instruction. Forty-eight hours post-
transfection, cells were harvested and processed to
evaluate the luciferase and β-galactosidase activities by
using Dual Light Luciferase System (Tropix, Bedford,
MA, USA) in a bioluminometer (TECAN, Infinite
200). Experiments were performed in triplicate and re-
peated independently twice. The ratio of firefly lucifer-
ase activity to β-galactosidase activity was expressed as
relative light units (RLU).
Luminescent proteasome assay
To individually measure the chymotrypsin-, trypsin- and
caspase-like proteasome activities in cultured cells, the
Proteasome-Glo™ 3 substrates Cell-Based Assay (Promega)
was used. LCLs were plated in 96-well plates at concentra-
tion of 2x104/well and incubated at 37°C overnight. The
day after, cells were treated with 100 μM MG132 for
2 hours (inhibitor control) and 0.1 mM H2O2 for 30 mi-
nutes (test treatment) before adding the three specific pro-
teasome substrates: Such-LLVY-Glow™ Substrate for the
Chymotrypsin-Like activity, Z-LRR-Glow™ Substrate for
the Trypsin-Like activity and Z-nLPnLD-Glo™ Substrate
for the Caspase-Like activity. Luminescence for each sam-
ple, performed in duplicate and in two separate experi-
ments, was read after 15 minutes in a plate-reading
luminometer (TECAN, Infinite 200).
Statistical analysis
Data were reported as means ± S.E. Statistical analysis
was performed with SPSS 13.0 software and the stu-
dent’s t-test was used for the statistical significance
(two-tailed, p < 0.05) of differences between means of
DS and control subjects. To validate the microarray
data, the average expression ratios (DS/controls) of
both array and qRT-PCR were subjected to Pearson’s
correlation analysis.
Results
Supervised analysis of pooled data of DS and control
samples
For the analysis of differentially expressed genes, six DS
LCLs were compared to six control samples. A first list of
3,416 differentially expressed genes was generated by
using a corrected p-value cut-off of 0.05. Of these, 1,051(30.7%) were up-regulated and 2,368 (69.3%) were down-
regulated, with a gene expression variation ranging from
0.67 to 3.04. No chr 21 gene resulted down-regulated. A
second list of genes was then generated by using a
corrected p-value cut-off of 0.01. In this case, a total of
406 transcripts resulted significantly either up-regulated
(n = 71; 17.5%) or down-regulated (n = 335; 82.5%)
(Additional file 1A). Supervised hierarchical clustering
of both the 4,490 and the 406 transcripts clearly distin-
guished between DS and control samples (Additional
file 1B, C).
Chr 21 expression profiles
Two hundred-twenty genes out of 449 genes annotated
on chr 21 (NCBI RefSeq 37.2) were detected in this
microarray analysis. Among these, 59 known genes
(13.1% of total chr 21 annotated genes) resulted differen-
tially expressed in DS vs controls (p < 0.05, FC ≥ 1.2), with
FC ranging from 1.20 to 2.57 and a mean DS/control ratio
of 1.36 ± 0.2. A graphic view of the differentially expressed
chr 21 genes is illustrated in Figure 1, that shows how a
substantial number of triplicated genes escapes the gene-
dosage rule. To identify functional categories associated
with the trisomic genes, the list of chr 21 deregulated
genes was submitted to a GO analysis. Results indicated
‘ATPase activity coupled to transmembrane movement of
substances’ (p = 0.005, FE 11.3), ‘cofactor metabolic process’
(p = 0.029, FE 5.8), ‘regulation of cholesterol biosynthetic
process’ (p = 0.031, FE 62.2) and ‘oxidative phosphoryl-
ation’ (p = 0.04, FE 9.2) as the major enriched categories
(Table 1). The analysis of the same genes, performed using
KEGG database, showed Parkinson’s (p = 0.01, FE 8.3),
Alzheimer’s (p = 0.02, FE 6.1) and Huntington’s (p = 0.03,
FE 5.5) diseases as the most deregulated biological path-
ways (Table 2).
Analysis of chr 21 gene expression variability among DS
and controls
To assess the expression variation of chr 21 genes
among DS and control samples, we focused the analysis
on the variability of all chr 21 transcripts present on the
array with FC ≥ 1.2 (n = 167). Among controls, 77 tran-
scripts (46.1%) had CV ≤ 0.2, 74 (44.3%) had 0.2 < CV <
0.5 and 16 (9,6%) had CV ≥ 0.5. Among DS samples, 110
transcripts (65.9%) had CV ≤ 0.2, 48 (28.7%) had 0.2 <
CV < 0.5 and 9 (5.4%) had CV ≥ 0.5 (Table 3). Fifty-five
transcripts were tightly regulated in both DS and con-
trols and among them, notably, mitochondrial-related
genes (ATP5O, ATP5J and NDUFV3), SOD1, DYRK1A
and cell-cycle related genes (Additional file 2). GO ana-
lysis of this gene subset revealed the enrichment of the fol-
lowing categories: ‘Cofactor metabolic process’ (p = 0.007,
FE 9.4), ‘ATPase activity, coupled to movement of sub-
stances’ (p = 0.0018; FE 15.9), ‘oxidative phosphorylation’
Figure 1 Average up-regulation ratios of chromosome 21
differentially expressed genes (p < 0.05).
Table 2 Enriched pathways of chromosome 21
up-regulated genes
Pathway term Genes % p-value FE













Table 1 Enriched GO categories of chromosome 21
up-regulated genes
GO term Genes %* p-value FE
ATPase activity, coupled to
transmembrane movement
of substances
ATP5O 6.2 0.005 11.3
ATP5J
ABCG1






ABCG1 3.1 0.031 62.2
SOD1
Oxidative phosphorylation ATP5O 4.7 0.04 9.2
ATP5J
NDUFV3
FE fold enrichment, *% of genes in category.
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ATP synthase complex, coupling factor F(o)’ (p = 0.016, FE
120.4), ‘regulation of cholesterol biosynthetic process’ (p =
0.019, FE 100.3) (Table 4). KEGG database showed the en-
richment of ‘oxidative phosphorylation’ (p = 0.03, FE 9.9)
besides Parkinson’s, Huntington’s and Alzheimer’s diseases
(Table 5). Neither GO enriched categories nor KEGG
pathways were associated to the 22 transcripts tightly reg-
ulated in controls (CV ≤ 0.2) and with little variation in
DS (0.2 < CV < 0.5).Genome-wide expression analysis, functional classes and
pathway perturbation
GO functional class scoring was performed by compar-
ing the list of the 406 differentially expressed genes to
the complete list of genes spotted on the array.
Our analysis revealed a down-regulation of the bio-
logical processes related to ubiquitin metabolism; cell
signalling, with a particular enrichment for the NF-kB
cascade; cell cycle; protein localization; regulation of
gene expression (Table 6). Among up-regulated categor-
ies, the most disrupted were those related to develop-
mental processes and to transport and localization, with
a strong enrichment of calcium ion transport (Table 7).
Table 3 Chromosome 21 transcripts sorted by the
coefficient of variation in both DS and control samples
DS samples
CV ≤ 0.2 0.2 < CV < 0.5 CV ≥ 0.5 TOTAL
CV ≤ 0.2 55 22 0 77
Controls 0.2 < CV < 0.5 49 19 6 74
CV ≥ 0.5 6 7 3 16
TOTAL 110 48 9 167
CV coefficient of variation, DS Down syndrome.
Table 5 Enriched pathways of the 55 chromosome 21
transcripts tightly regulated in DS and controls (CV ≤ 0.2)
Pathway term Genes % p-value FE








Oxidative phosphorylation ATP5O 7.1 0.03 9.9
ATP5J
NDUFV3
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as the pathway mostly influenced by trisomy 21 (p = 2.9E-5;
FE 4.8). Among genes involved in the ubiquitin-dependent
proteolysis, a number of E2-conjugating enzymes (UBE2A,
UBE2B, UBE2H), E3-ligases (UBE3A, ITCH, SMURF2,
F-box proteins, MIB1) and deubiquitinating enzymes
(USP1, USP2, USP8, USP12, USP15, USP28, USP32,
USP33, USP34, USP38, USP47) resulted down-regulated.
Microarray data were validated by qRT-PCR on 11 differ-
entially expressed genes with different functions and by
comparing their average expression ratios (DS/controls)
with those of the array (Additional file 3).Selection of possible therapeutic compounds
Connectivity map and PASS-assisted exploration were used
to identify compounds whose molecular signatures coun-
teracted those of DS lymphoblasts and to predict their
therapeutic potential, respectively. We found 17 compoundsTable 4 GO categories of the 55 chromosome 21
transcripts tightly regulated in DS and controls (CV ≤ 0.2)
GO term Genes %* p-value FE




ATPase activity, coupled to
transmembrane movement
of substances
ATP5O 9.5 0.0018 15.9
ATP5J
ABCG1




ATP synthase complex, coupling
factor F(o)




ABCG1 4.8 0.019 100.3
SOD1
FE fold enrichment, *% of genes in category.with enrichment score < −0.7 (Additional file 4). Among
these, adiphenine, eticlopride and vigabatrin display a pre-
dicted proteasome ATPase inhibitor activity (Pa score
0.72, 0.65 and 0.59, respectively). Adiphenine also displays
a putative ubiquitin thiolesterase inhibitor and a prote-
asome endopeptidase complex inhibitor activity (Pa score
0.58 and 0.56, respectively). Finally, oxybenzone display a
free radical scavenger activity (Pa 0.79).Validation of some significantly deregulated GO
categories
Protein ubiquitination and proteasome activity
Ubiquitinated protein levels were measured by Western
blot with or without proteasome block by MG132. Results
in both LCLs and fetal fibroblasts showed a reduction of
the ubiquitination state in DS resting cells and an increase
following MG132 treatment (Figure 2A, B).
As chronic oxidative stress (OS) is a feature of DS and a
defective response to OS is known to occur in DS with ac-
cumulation of protein damage [58], ubiquitinated protein
levels were also measured after incubation with 0.1 mM
H2O2. DS cells showed a trend to increase ubiquitin-
bound proteins after OS induction. After H2O2 with-
drawal, DS cells showed a more efficient recovery in the
first two hours compared to controls (Figure 3). As the in-
crease of ubiquitination following proteasome blocking
suggested a possible involvement of the proteasome, the
three proteasome activities were tested in LCLs before
and after incubation with H2O2. Proteasome activity assay
revealed a significant increase in the trypsin-like and in
the chymotrypsin-like activities (p < 0.01) in DS subjects,
Table 6 Enriched GO categories of down-regulated genes (p < 0.01), sorted by p-value
Biological process GO term N. of genes %* p-value FE
Ubiquitin metabolism ubiquitin-dependent protein catabolic process 16 5.4 5.2E-6 4.3
modification-dependent protein catabolic process 25 8.5 1.4E-5 2.7
proteolysis involved in cellular protein catabolic process 25 8.5 2.9E-5 2.6
ligase activity 17 5.8 0.001 2.6
proteolysis 29 9.8 0.009 1.6
ubiquitin-protein ligase activity 8 2.7 0.013 3.2
proteasomal ubiquitin-dependent protein catabolic process 6 2.0 0.025 3.6
Cell signalling positive regulation of I-kB kinase/NF-kB cascade 9 3.1 0.0002 5.5
positive regulation of protein kinase cascade 10 3.4 0.0024 3.5
positive regulation of signal transduction 12 4.1 0.01 2.4
Protein localization establishment of protein localization 25 8.5 0.002 2.0
Cell cycle mitotic cell cycle 14 4.7 0.008 2.3
cell cycle phase 15 5.1 0.009 2.2
M phase of mitotic cell cycle 10 3.4 0.013 2.7
mitosis 9 3.1 0.031 2.4
nuclear division 9 3.1 0.031 2.4
interphase 6 2.0 0.033 3.3
Regulation of gene expression gene expression 62 21.0 0.022 1.3
mRNA processing 12 4.1 0.023 2.2
RNA splicing 11 3.7 0.024 2.3
Vescicle related ER to Golgi vesicle-mediated transport 4 1.4 0.033 5.6
FE fold enrichment, *% of genes in category.
Table 7 Enriched GO categories of the up-regulated
genes (p < 0.01), sorted by p-value
Biological
process







calcium ion transport 5 8.3 0.001 10.6
transmembrane
transport
7 11.7 0.01 3.7
metal ion transport 6 10.0 0.016 3.9
localization 17 28.3 0.022 1.7
cation transport 6 10.0 0.032 3.3
transport 15 25.0 0.034 1.7
ion transport 7 11.7 0.035 2.8
establishment of
localization
15 25.0 0.037 1.7
Development cellular developmental
process
14 23.3 0.002 2.5
anatomical structure
development
17 28.3 0.004 2.0
cell differentiation 13 21.7 0.005 2.4
system development 16 26.7 0.005 2.1
multicellular organismal
development
17 28.3 0.015 1.8
organ development 12 20.0 0.021 2.1
FE fold enrichment, *% of genes in category.
Granese et al. BMC Medical Genomics 2013, 6:24 Page 8 of 17
http://www.biomedcentral.com/1755-8794/6/24both in basal and OS conditions, while no differences
were observed for the caspase-like activity (Figure 4).
IkB-alfa/NF-kB
NF-kB is finely regulated by a complex network of gene
products and post-translational modifications. To demon-
strate if a NF-kB defect occurs in DS, we choose to analyse
the down-stream product of the NF-kB cascade, i.e. the be-
haviour of p50/p65 and of its inhibitors in DS cell lines.
Levels of p50, p65, IkB-alfa and phospho-IkB-alfa proteins
were assessed by Western blot using specific antibodies in
DS and control samples. Results showed a significant re-
duction of p65 levels in the nuclear fractions and a signifi-
cant increase of IkB-alfa in the cytosolic fractions of DS
subjects, in both the dephosphorylated and phosphorylated
forms (Figure 5A, B, C). No difference was observed for
NF-kB p50 subunit levels (data not shown). Luciferase
assay confirmed a significant reduction of NF-kB transcrip-
tional activity in DS LCLs (p < 0.05) (Figure 5D). Immuno-
precipitation of IkB-alfa in cytosolic fractions and subsequent
Western blot with specific anti-ubiquitin antibody showed
a reduction of the ubiquitinated levels of this inhibitor
under basal conditions in DS fractions (Figure 6A). Ubi-
quitination levels returned similar to controls after prote-
asome blocking (Figure 6B).
Figure 2 Western blot analysis of total ubiquitin-bound protein levels. A) Western blot performed on lymphoblasts and fetal fibroblasts in
basal conditions and following proteasome blocking (40 μM MG132 for six hours). B) Histograms show the average protein ubiquitination of
lymphoblasts derived from two controls and two DS subjects, normalized on tubulin levels. * p < 0.05.
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DYRK1A, DSCR1 and the members of the NFAT tran-
scription factors were evaluated by RT-PCR and West-
ern blot. We observed a significant upregulation of
DYRK1A, DSCR1 and NFATc4 (about 2-fold increase)
and a down-regulation of NFATc2 (69% reduction) and
NFATc1 (49% reduction) expression profiles in DS LCLs
compared to controls (Figure 7A). No difference was ob-
served for NFATc3. At protein level, we confirmed the
significant reduction of NFATc2 and the increase of
DYRK1A and DSCR1 (Figure 7B) while no differenceFigure 3 Ubiquitin-bound proteins in LCLs from a DS and a control su
ubiquitin-bound proteins in lymphoblasts from a DS and a control subject
30 minutes) and after 1, 2 and 4 hours of recovery. B) relative densitometrywas observed for NFATc1 and NFATc4 (data not shown).
To assess NFAT nuclear translocation, Western blot exper-
iments were performed upon induction of calcium fluxes
through PMA/ionomycin. Results showed a reduction of
NFATc2 nuclear levels following stimulation, suggesting
the presence of mechanisms acting to inhibit its transloca-
tion (Figure 8).
Finally, soluble DSCR1 protein levels were investigated
before and after proteasome blocking. Results showed a
reduction of soluble DSCR1 levels in both samples after
MG132 treatment, with a more marked effect in DSbject in basal and OS conditions. A) Western blot analysis of
in basal conditions, under oxidative stress (0,1 mM H2O2 for
.
Figure 4 Proteasome activity assay from LCLs, in basal
conditions and after treatment with 0,1 mM H2O2 for
30 minutes. Histograms show the average of the activities of DS
subjects (n = 3) versus controls (n = 3), evaluated in duplicate and
repeated twice. * p < 0.05.
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controls (Figure 9).
Discussion
In spite of the great efforts made to analyze the effects
of dosage imbalance at molecular level, the pathogenesis
of DS is still unclear. So far, expression studies per-
formed with distinct approaches led to inconclusive re-
sults, thus underlining the importance of integrating
microarray data with functional validation of selected
pathways.
The present study was aimed at analyzing gene expression
profiles in LCLs from DS and controls to identify genes and
metabolic pathways involved in DS pathogenesis, with an
emphasis toward chr 21 genes. To select reliable GO classes,
two distinct web-based softwares working on different statis-
tic algorithms (DavidBioinformatics and GOTM) were used.
These GO classes where further analysed to provide experi-
mental evidence of their disruption in DS.
Despite some inherent limitations, the utility of LCLs
is increasingly recognized in both genetic and functional
studies [59]. Considering the similarity of the expression
and regulation of certain genes between LCLs and neu-
rons, LCLs have been used as surrogate cells in studies
of neurological disorders as in the case of Parkinson’s
disease [60,61] and Alzheimer’s disease [62]. LCLs have
also been successfully used to study mitochondrial and
organellar dysfunction as in the case of autophagy injuvenile neuronal ceroid lipofuscinosis [63]. Beside the
present study, LCLs have been used in expression stud-
ies of chr 21 genes in three previous works [21,23,38]
where it was demonstrated that the variance on gene ex-
pression levels due to culture conditions is extremely
low in this cell model [21]. Moreover, Merla et al., [64]
established six independent LCLs for the same individual
and compared expression levels for 25 chr 21 genes find-
ing a strong correlation ranging from 0.8 to 0.92. In this
study, to maximize the quality of LCLs, each aliquot of
LCLs was maintained in culture for no longer than
3 months (less than 160 ‘population doubling levels’)
and cells were karyotyped before microarray analysis
and before each experimental validation to exclude the
possibility of chromosomal rearrangements (other than
full trisomy 21).
Overexpression of chr 21 genes
Our results showed a significant up-regulation of a sub-
set of 59 chr 21 genes (p < 0.05) with a mean DS/control
ratio of 1.36 ± 0.2. This confirms that most trisomic
genes escape the predicted gene-dosage rule of 1.5-fold
increase and underscores the existence of complex and
unravelled mechanisms of transcriptional regulation
[65]. In the present study, GO analysis of the over-
expressed chr 21 genes indicated ATPase activity
coupled to transmembrane movement of substances and
oxidative phosphorylation as the major enriched categor-
ies. This result is in agreement with previous gene
expression studies in fetal DS cerebral cortex, heart and
trophoblasts [5,7,13,15] in which the most consistently
disregulated chr 21 genes were those involved in mito-
chondrial function related metabolic pathways, such
as ATP5O and ATP5J (encoding two mitochondrial ATP
synthase subunits), NDUFV3 (subunit of NADH
dehydrogenase), and SOD1 (involved in antioxidant
defense system). Mitochondrial dysfunction has been
proposed in the pathogenesis of DS for years. In par-
ticular, deficit of oxidative phosphorylation due to a
deregulation of the mitochondrial respiratory chain
complexes I, III and V [34,35,66-68], increased levels of
the Krebs cycle enzymes (aconitase and NADP-linked
isocitrate dehydrogenase) [69] and impaired mtDNA re-
pair systems [70] were described in human DS cells. In
isolated mitochondria from DS mice cortex, a decreased
membrane potential and ATP content and selective de-
fects in Complex-I mediated respiration were also found
[71]. Furthermore, a close relationship between mito-
chondrial abnormalities and oxidative damage has been
described in DS brains and fibroblasts [72]. Mitochondrial
dysfunctions can result either in decreased ATP levels, or
in increased ROS production [35,73]. Mitochondrial dys-
function was also described in neurodegenerative diseases
such as Alzheimer’s, Parkinson’s and Huntington’s diseases
Figure 5 NF-kB p65, IkB-alfa and phospho-IkB-alfa in LCLs and fibroblats and relative densitometry. A) Western blot of NF-kB p65 nuclear
levels and B-C) IkB-alfa and phospho-IkB-alfa cytosolic levels LCLs and relative densitometry. p65, IkB-alfa and phospho-IkB-alfa protein levels in
fetal fibroblasts from one DS subject and one control are shown as well. As internal controls, tubulin and H1 histone were used for cytosolic and
nuclear marker proteins, respectively. D) NF-kB Luciferase assay in lymphoblasts. Histograms show the average of the activity, expressed as relative
light units (RLU), of DS subjects (n = 3) versus controls (n = 3) normalized on the average of the b-galactosidase activity. Experiments were
performed in triplicate and repeated twice. * p < 0.05.
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when the trisomic genes, upregulated in the present gene
expression study, were submitted to pathway analysis,
Alzheimer’s, Parkinson’s and Huntington’s diseases were
identified as the most deregulated, in agreement with the
meta-analysis from heterogeneous human and mouse DS
data sets [27]. Finally, when only the amplified chr 21
genes tightly regulated in DS and in control subjects were
submitted to in silico analysis, the same categories and
pathways were identified. Taken together, these findings
suggest that genes directly or indirectly involved in the oxi-
dative phosphorylation, ATPase activity and, in general, in
mitochondrial function, may have a role in the pathogen-
esis of DS phenotypes.
Genome-wide deregulation and pathway perturbation
induced by trisomy 21
The genome-wide expression analysis revealed that
30.7% and 17.5% of genes were up-regulated at p < 0.05and p < 0.01, respectively. A low percentage of up-
regulated genes was also reported in two previous stud-
ies on LCLs, showing that 29% and 39% of genes were
up-regulated, respectively [21,23]. In this study, genes in-
volved in ubiquitin metabolism, cell signalling (with a
particular enrichment of NF-kB cascade), cell cycle, pro-
tein localization and regulation of gene expression were
down-regulated, and genes involved in developmental
processes and calcium ion transport were up-regulated.
The latter results are in agreement with previous
genome-wide studies that reported the impairment of
GO categories associated to developmental processes,
both in fetal and adult DS biomaterials [9,14], as well as
of calcium/potassium signalling on cell-free mRNA from
amniotic fluid [78].
At mRNA level, while the ubiquitin pathway was
reported as deregulated in DS trophoblasts and in
rRNA-depleted samples from DS endothelial progenitor
cells (EPCs) [15,79], NF-kB cascade, linked to the
Figure 6 Ubiquitination of IkB-alfa in basal conditions (A) and after proteasome blocking with 40 μM MG132 for six hours (B).
Cytoplasmic extracts were immunoprecipitated for IkB-alfa and then analyzed by western blot using an antibody against ubiquitin. IgG H and IgG
L indicate immunoglobulin heavy and light chains in the immunoprecipitates that cross-react with the secondary antibody.
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in the present study for the first time. The close relation
between the ubiquitin-mediated proteolysis and NF-kB
and their relevance to a wealth of human disorders
make these two pathways attractive candidates for DS
pathogenesis.
The ubiquitin-dependent proteolysis
The UPS is the major proteolytic pathway used by
eukaryotic cells to metabolize proteins [80]. Proteins to
be degraded are covalently linked to a polyubiquitin
chain by three different enzymes and then targeted to
the 26S proteasome where are disassembled in small
peptides, amino acids and ubiquitin monomers. UPS isFigure 7 Analysis of DYRK1A, DSCR1 and NFATc1-4 gene products in
pools of DS subjects (n = 3) versus controls (n = 3). All data are expressed re
B) Western blot of total protein levels. * p < 0.05.known to metabolize misfolded, oxidized and damaged
proteins, but also proteins involved in signal transduc-
tion, cell cycle regulation, differentiation and develop-
ment, cellular response to stress, regulation of the
immune and inflammatory response. A link between
protein synthesis and degradation by UPS has been pro-
posed [81]. Hence, derangements in this system, that
can be associated to loss of function (mutation in an
ubiquitin system enzyme or target substrate) or gain of
function (abnormal or accelerated degradation of the
target protein) could underlie, directly or indirectly, the
pathogenesis of many diseases, including some features
belonging to the DS spectrum. In particular, accumula-
tion of ubiquitin conjugates and/or inclusion bodiesLCLs. A) Relative quantification. Histograms show mRNA levels of
latively to control subjects, to which is assigned a value of 1-fold (1x).
Figure 8 Analysis of activation and nuclear translocation of
NFATc2, induced by PMA/Ionomycin. As internal controls, tubulin
and H1 histone were used for cytosolic and nuclear marker proteins,
respectively. * p < 0.05.
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array of chronic neurodegenerative diseases, such as the
neurofibrillary tangles of Alzheimer’s disease (AD), brain
stem Lewy bodies (LBs) in Parkinson’s disease (PD) and
intracellular bodies in Huntington’s disease [82]. In these
cases, an involvement of the UPS was suggested [83-85].
So far, no data were available on the ubiquitination sta-
tus and proteasome activity in human DS. By means of a
protein screen by SDS-page, a study showed an increase
of the proteasome zeta chain, an alpha subunit of the 20S
proteasome, and of isopeptidase T, a deubiquitinating en-
zyme, in fetal DS brain [86]. More recently, a study on the
cerebellum of Ts65Dn mice showed a reduction of the
proteasome chymotrypsin-like activity and an increase of
ubiquitinated proteins [87], results possibly ascribable toFigure 9 Western blot analysis of DSCR1 protein levels in basal
conditions and following proteasome blocking with 40 μM
MG132 for six hours in lymphoblasts from 2 DS and 2 control
subjects. * p < 0.05.the increased levels of beta-amyloid found in Ts65Dn
mice brains [88].
The present study in human cell lines shows for the
first time that, under basal conditions, there is a reduc-
tion of ubiquitinated protein levels in DS. This observa-
tion may either depend on defective ubiquitin-protein
ligase activity (as suggested by microarray data) or on in-
creased proteasome function, as demonstrated by the in-
crease of two out of the three proteasome activities.
Under OS, we observed an increase of ubiquitinated
proteins in DS compared to the control sample. In the
recovery period, ubiquitinated proteins were efficiently
cleared in DS, probably due to the observed increase of
the proteasome activities during OS. Previous studies
have shown that chronic OS is a feature of DS
[35,36,71,89-92]. Increased protein damage has also been
shown in DS [58]. These observations may explain the
increased proteasome activity, the accumulation of Ub-
bound proteins after proteasome blocking with MG132
and, at least in part, the reduction of ubiquitin-bound
proteins. These findings offer a new perspective to study
this system in association to relevant DS pathological
features, such as neurodegeneration, autoimmune disor-
ders and predisposition to cancer.
IkB-alfa/NF-kB
The UPS is implicated in numerous cellular processes
including activation of transcription factors such as NF-
kB. The NF-kB family of transcription factors is critical
in the development and maintenance of the immune
system. Five NF-kB subunits exist and the most abun-
dant and active form is a heterodimer composed of p50
and p65. Generally, this heterodimer is sequestered in
the cytosol by one of the IkB inhibitors, most commonly
IkB-alfa and is activated only upon IkB phosphorylation
and subsequent proteasome mediated degradation [47].
Since this transcription factor is connected to a wide
array of immune and inflammatory disorders, along with
cell apoptosis and delay of cell growth, disruption of its
pathway could play an important role in DS pathogen-
esis. In the present study, the GO analysis showed a
down-regulation of the NF-kB cascade. Our experimen-
tal data provide the first evidence of a reduction of the
NF-kB p65 subunit in DS nuclear fractions and of a
significant reduction of its transcriptional activity.
Along with this observation, cytosolic IkB-alfa levels
were increased, in both the phosphorylated and
dephosphorylated form. Ubiquitin-bound IkB-alfa was
however reduced. These results, in agreement with the
data of the total protein ubiquitination state, may be
due to proteasome hyperfunction or to a defect of spe-
cific ubiquitin ligases activities, such as F-box proteins,
or the recently described MIB1 [93], downregulated in
this microarray experiment. As NF-kB signalling is
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[94,95], further studies on the regulation of NF-kB by
ubiquitination in DS may add new clues to the patho-
genesis of DS.
An additional level of interest comes from recent evi-
dence of an interplay between NF-kB and NFAT pathway.
In fact, NF-kB-inducing kinase interacts with and specific-
ally phosphorylates the C-terminal region of DSCR1 in
immortalized hippocampal cells as well as in primary cor-
tical neurons, increasing DSCR1 protein stability and
blocking its proteasomal degradation [44]. This could lead
to an increase in soluble and insoluble DSCR1 levels that
are cytotoxic [29]. Moreover, DSCR1 overexpression stabi-
lizes IkB-alfa and decreases the steady-state activity of NF-
kB, thus inhibiting the induction of genes involved in the
inflammatory response [30].
The role of DYRK1A/DSCR1/NFAT genes in DS
The nuclear factors of activated T cells (NF-ATs) are a
family of transcription factors that transduce calcium
signals in the immune, cardiac, muscular, and nervous
systems [96]. Like their distant relatives, the Rel family,
which includes NF-kB, NFATs are located in the cyto-
plasm of resting cells and are activated for nuclear trans-
location [97]. Calcium signalling activates calcineurin
and induces the movement of NFAT proteins into the
nucleus, where they cooperate with other proteins to
form complexes on DNA. As DYRK1A and DSCR1
regulate NFAT nuclear translocation, in the present
study the DYRK1A/DSCR1/NFAT genes were analysed.
DYRK1A at both RNA and protein levels resulted sig-
nificantly overexpressed in DS. The same result was
obtained for DSCR1, while a reduction of NFATc2 was
observed at mRNA and protein level in DS resting cells.
Reduction of NFATc2 was also observed in the nuclear
fractions of DS after calcium flows stimulation. Together
with the reduced NF-kB activity, this observation sug-
gests the presence of a transcriptional regulation deficit
in DS.
Conclusions
Results from the present microarray analysis in human
LCLs show that the UPS functioning is impaired in DS.
Among genes contributing to the ubiquitin mediated pro-
teolysis and represented on the array, a number of E2-
conjugating enzymes (such as UBE2A, UBE2B, UBE2H)
and E3 ligases (such as UBE3A, ITCH, SMURF2, MIB1
and some F-box proteins) resulted down-regulated. Add-
itional bioinformatic tools such as Connectivity Map and
PASS analysis add supportive evidence of the involvement
of the UPS in the pathogenesis of DS. Experimental data
confirm a reduction of Ub-bound proteins and an in-
creased proteasomal acitivity. Proteasome activity may be
accelerated by increased damaged or misfolded proteinsand/or by chronic oxidative stress, a known biochemical
feature of DS resulting from either gene dosage effect of
certain chr 21 genes (i.e. SOD1, CBS, APP) or mitochon-
drial dysfunction [36,89,98,99].
Increased proteasome activity, along with defective
ubiquitination, may lead to reduction of Ub-bound pro-
teins, including critical regulators of cellular homeostasis
such as transcriptional activators or their inhibitors. Ex-
pression analysis pointed to a down-regulation of NF-kB,
the final actor of a complex pathway of signal transduc-
tion finely modulated by ubiquitination at several levels
[94]. Interestingly, definition of crosstalk between NF-kB
signalling pathway, ubiquitin-dependent proteolysis and
the critical chr 21 gene DSCR1 is still ongoing.
Because of its central role in the cell life, the prote-
asome has become a target for synthetic and natural
drugs for the prevention and treatment of several condi-
tions [100-102]. An example of the medical importance
of its inhibition could be the stabilization of the tran-
scription factor NF-kB, required to preserve cell viability
in response to environmental stress or cytotoxic agents
[103-105]. Furthermore, as suggested by our findings,
also the DSCR1 protein levels, overexpressed in trisomic
subjects, may be regulated by the proteasome inhibition.
Recent biochemical and epidemiological studies indicate
that dietary minor components, such as polyphenols, may
have a role in the defense against the OS in vivo [106].
Among the different phenolic compounds, epigallocatechin-
3-gallate (EGCG), the major catechin of green tea, mitigates
OS and inhibits the chymotrypsin-like activity of the prote-
asome [107-110]. Interestingly, the over-expression of
DYRK1A can also be modulated by EGCG [111] and trans-
genic mice overexpressing this gene and presenting cogni-
tive impairment, rescue the cognitive phenotype after a
polyphenol-based diet [112]. Our functional analyses
revealed an increase of the proteasome chymotrypsin-
like activity in DS subjects and the Connectivity map
and PASS-assisted exploration of our microarray data
suggested that some compounds with proteasome in-
hibitor activity could revert the biological status of DS.
In conclusion, the present work offers new perspectives to
better understand the pathogenesis of DS disease and sug-
gests a rational for innovative approaches to DS treatment.
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